Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related morbidity and mortality globally, and the disease burden is especially pronounced across Asia (1). The diversity of underlying risk factors and the intrinsic heterogeneity of HCC highlight the need for validated prognostic instruments to improve outcome estimation (2). Spontaneous rupture of HCC (SRHCC)—also coined as perforation of visceral peritoneum—with an incidence of up to 5%, remains one of the most feared and prognostically important presentations where immediate survival and long-term oncologic control must be considered together (3,4). In this context, Xu et al. report an important surgical-outcomes analysis of SRHCC in a hepatectomy cohort, examining not only the survival outcomes but also whether operative strategy can improve the prognosis of SRHCC patients (5). In a single-centre retrospective series [2009–2011], the authors analysed 2,486 patients undergoing liver resection, including 118 with SRHCC, while excluding patients with other malignancies and those dying within one month after surgery, thus focusing on post-hepatectomy survivors. Using inverse probability of treatment weighting (IPTW), SRHCC remained independently associated with worse recurrence-free survival (RFS) and overall survival (OS). The study also clarifies predictors that may flag rupture biology at presentation: symptoms, poorer Child-Pugh class, and tumour size >3 cm were independently associated with SRHCC. Anatomic resection improved median OS and RFS compared with non-anatomic approaches. Patients with rupture still experienced worse median OS and RFS compared with non-rupture. This matters because it supports rupture as an adverse event that persists beyond the immediate physiologic crisis. Taken together, these findings position rupture beyond merely a perioperative complication, but also a biologic-mechanical inflection point.

In this editorial, we discuss cell mechanobiology, Gompertzian slowing, and growth-induced stress linking size to capsular failure. We also integrate these factors with evidence that early haemostasis and the ability to proceed to definitive HCC therapy shape outcomes after rupture.

Size and volume matters

Clinicians often treat tumour diameter as a linear marker of stage. Biologically, cell number scales with tumor volume which grows cubically with diameter. That is why a 2 cm sphere contains ~8 times the cell burden of a 1 cm sphere, a 3 cm sphere contains ~27 times, and a 5 cm sphere contains ~125 times. This mathematics partly explains the Xu et al. results that size >3 cm was associated with risk of SRHCC. Size is a proxy for a step-change in mass, vascular demand, and internal stress, not an arbitrary cut-point. The size-volume correlation aligns with outcome data. Strikingly, in Xu et al.’s multivariable model, tumour number, cancer embolus, and capsule all lost significance, while size, symptoms, and Child-Pugh class dominated—again implicating bulk and host reserve rather than intrinsic tumor multiplicity in rupture biology. In a meta-analysis of 24 cohorts (n≈23,747) comparing giant (≥10 cm) vs. non-giant HCC, non-giant tumours had superior long-term OS [hazard ratio (HR) ~0.53] and disease-free survival (DFS) (HR ~0.62), while short-term safety signals (30-day mortality and postoperative complications) were not significantly different (6). This suggests size and volume are biological discriminators. To note, while the staging systems use cut-offs of 2 and 5 cm, Xu et al. report 3 cm cut-off. This 3 cm rupture threshold sits awkwardly between the 2 and 5 cm, reinforcing that rupture reflects a continuous volume-stress relationship rather than any administratively chosen tumour diameter.

Growth kinetics matter

Early tumor expansion can look “exponential” because diffusion distances are short, oxygen and nutrients are relatively adequate, and microenvironmental constraints are weaker. As lesions enlarge, growth typically decelerates (Gompertzian behaviour): hypoxia, perfusion heterogeneity, nutrient gradients, and rising cell loss progressively limit net expansion. Thus, large tumours can have immense cell burden while only a minority of cells are actively dividing. Hence rupture risk should not be simplistically attributed to high proliferation, but rather to accumulated mass interacting with fragile vasculature and constrained liver architecture (Figure 1). This explains why HCC ruptures despite the tumour no longer showing fast net growth—the trigger may instead be haemorrhage into a high-pressure, poorly compliant mass at the liver surface. Growth generates residual stresses and stress gradients can drive mechanical instabilities and drives a causal chain of more cells → more volume → higher internal pressure/interface tension → fragile neo-vessels + haemorrhage → capsular/parenchymal failure → rupture. Notably, angiography demonstrates active contrast extravasation in only 13–36% of cases, reinforcing that no blush does not equal no rupture (7). The independent survival advantage associated with tumor encapsulation in SRHCC is consistent with the concept that a defined tumor-liver interface may modulate how intratumoral pressure and haemorrhage are transmitted to the surrounding parenchyma. Notably, tumor encapsulation independently improved both OS and RFS in Xu et al.’s cohort, reinforcing that mechanical boundary integrity is prognostically meaningful in rupture biology.

Figure 1 Determinants and mechanisms for HCC rupture, showing how HCC rupture represents a mechanical failure. HCC, hepatocellular carcinoma.

Anato-pathology matters

The rupture cohort in Xu et al. was not enriched for multifocal disease, macrovascular invasion, or viral burden, but instead for large tumours (99% vs. 74%), Child-Pugh B/C class (14% vs. 2.4%), high symptom burden (87% vs. 43%), and reduced tumor encapsulation (68% vs. 79%), supporting rupture as a geometry-plus-host failure state rather than a marker of intrinsic oncologic aggressiveness. Subcapsular or exophytic tumours may indeed be more peripheral and sometimes technically more amenable to wedge/segmental resections; however, rupture itself is still associated with worse long-term OS/RFS in this surgical cohort. In multivariable modelling, SRHCC was associated with worse OS [HR 1.95, 95% confidence interval (CI): 1.57–2.43] and worse RFS (HR 1.60, 95% CI: 1.32–1.94) (5). Similarly, anatomic liver resection may be a surrogate for biologically adequate extirpation of segmental portal territories and microscopic spread. In multivariable analysis OS was favourable in patients treated with anatomic resection (HR 0.47, 95% CI: 0.27–0.81) (5). Importantly, rupture risks intraperitoneal implantation metastases, reinforcing why rupture remains prognostically adverse even when the primary lesion is resected (8). This is important consideration as the widely accepted Barcelona Clinic Liver Cancer (BCLC) staging system stratifies patients only by tumour burden, liver function, and performance status without any mention of acute haemorrhagic catastrophe (9). Paradoxically, although BCLC stage continues to stratify survival after rupture in the Xu et al.’s cohort, the BCLC framework itself provides no language for haemorrhagic catastrophe, leaving clinicians to manage the deadliest phase of HCC outside its decision architecture. Furthermore, it must be noted that according to 8th edition of TNM staging system, SRHCC belong to cT4 and corresponding stage IIIB and this is lower than stage IVA assigned to node positivity and stage IVB to metastatic disease.

Survive first, then treat

It is useful to juxtapose Xu et al. report with the multicentre cohort from France which studied SRHCC as an acute event (10). In this multicentre cohort of 112 patients with SRHCC, haemostatic therapy was delivered in 61 patients (54.4%)—predominantly embolization (n=51), with fewer undergoing surgery (n=6) or combined embolization + surgery (n=4); subsequently, about one-third received definitive HCC treatment, and those who proceeded to delayed HCC therapy had markedly better OS (HR 0.35, 95% CI: 0.20–0.61). The two studies imply a staged narrative: mechanical catastrophe first (haemostasis), oncologic trajectory second (definitive therapy), and surgical philosophy third (anatomic adequacy among resected survivors). Two decades earlier, Lai et al. synthesised the acute-phase evidence and showed that transarterial embolization achieves haemostasis in most series (success ~53–100%), with lower short-term mortality than open surgical haemostasis (7). They also emphasised transarterial embolization (TAE) is best suited to patients with reasonable hepatic reserve and without complete portal vein thrombosis, and it appears rarely beneficial when bilirubin is markedly elevated. In that same review, one-stage emergency hepatectomy carried striking in-hospital mortality (16.5–100%), whereas staged resection (performed after physiologic and hepatic recovery) was associated with far lower in-hospital mortality (0–9%) and more credible longer-term survival. The reported interval between stages varied widely (roughly 10–126 days), underscoring that timing remains a clinical judgment rather than a settled rule. This staged logic mirrors the LIFE-Triad of Emergency General Surgery, which argues that survival in catastrophic surgical disease depends first on physiological rescue through continuous emergency practice, second on data-driven learning from registries, and only third on codified oncologic or procedural guidelines (11). In ruptured HCC, haemostasis corresponds to the first limb of the triad, delayed definitive cancer therapy to the second, and decisions about anatomic adequacy to the third. This explains why survival emerges from sequencing rather than from any single intervention. This staged survival-first paradigm, however, carries an oncologic tension: a large meta-analysis of over 135,000 HCC patients shows that apparent safety of treatment delay is largely explained by selection of patients with smaller, more indolent tumours, while biologically aggressive cancers tend to declare themselves earlier (12). In ruptured HCC, prolonged intervals between haemostasis and definitive therapy may risk tumour progression even if population-level survival curves appear neutral. It is possible that TAE reduces this risk.

Selection bias and caution

In the French multicentre rupture cohort, more than half of all patients were removed from the oncologic pathway at the outset as 28.6% died within 30 days and a further 27% were triaged directly to palliation (10). Importantly, Xu et al.’s cohort is not a rupture cohort but a post-selection surgical survivor cohort, because all patients who died within one month, including those lost to haemorrhage, liver failure, or early decompensation, were excluded (5). Thus, the reported benefit of anatomic resection applies only to those who first survive the rupture. Only 28 of 118 SRHCC patients had anatomic liver resection. In this context, anatomic resection likely reflects not only superior oncologic clearance but also the fact that the patient had survived the rupture with sufficient hepatic and hemodynamic reserve to permit oncologic surgery at all, making it a marker of salvageability as much as of surgical case selection and technical finesse. What remains unmeasured in the Xu cohort is the critical first-year attrition layer, where post-hepatectomy liver failure, renal injury, and cirrhotic decompensation determine survival, meaning that long-term oncologic curves emerge only after a large physiologic filter has already been applied. Because competing risks were not formally modelled, early liver-failure and renal deaths are statistically absorbed into recurrence and survival curves, further blurring tumor biology with post-rupture physiologic collapse. Because no coagulation, inflammatory, or portal-hypertension biomarkers were incorporated, the models cannot separate haemorrhagic propensity from simple tumor-volume stress. Moreover, the apparent dominance of ‘tumor size >3 cm’ as a rupture predictor reflects quasi-separation—nearly all ruptured cases exceeded this threshold. This resulted in extreme odds ratios that appear statistically striking but are biologically coarse. As IPTW was used primarily to preserve small rupture subgroups rather than to fully emulate randomisation, the reported hazard ratios reflect weighted survival projections rather than causal effects and remain vulnerable to confounding by physiologic selection and operative indication. Since non-anatomic resections in ruptured HCC frequently represent damage-control surgery under haemorrhagic constraint rather than oncologic intent, residual confounding by surgical urgency is inevitable and cannot be neutralised by weighting alone. Readers should avoid mistaking survival after physiologic selection for oncologic superiority.

Physiologic optimisation

Meta-analytic data show that perioperative branched-chain amino acid supplementation (13) reduces postoperative infection and ascites and shortens hospital stay, while perioperative corticosteroids (14) attenuate bilirubin rise, systemic inflammation, and overall complication rates and hence remain important considerations in SRHCC management protocols. Inflammatory indices like platelet lymphocyte ratio, neutrophil lymphocyte ratio, albumin-bilirubin index, and alike aid to stratify survival and treatment tolerance across HCC therapies and could be particularly relevant for triaging rupture survivors (15). Optimisation with prehabilitation initiatives and enhanced recovery programs may be equally important determinants of perioperative and oncologic outcomes as size, growth kinetics, and pathological determinants.

Taken together, these datasets suggest that SRHCC represents an interplay between tumour geometry (size and volume) and anato-pathologic architecture, with prognosis determined as much by host reserve as by tumour biology. The logical next step is a rupture-specific risk framework that integrates liver function, physiologic state, and imaging surrogates of mechanical vulnerability (such as protrusion and exophytic geometry) to guide triage, haemostasis, and the timing of definitive therapy. In a modern rupture ecosystem characterized by selective embolization, advanced critical care, and evolving systemic therapies, such an approach has the potential to meaningfully improve outcomes for patients with SRHCC.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-1-0036/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Selby LK, Tay RX, Woon WW, et al. Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore. J Hepatobiliary Pancreat Sci 2017;24:143-52. [Crossref] [PubMed]
2. Xia C, Chen Y, Zhu Y, et al. Identification of DLAT as a potential therapeutic target via a novel cuproptosis-related gene signature for the prediction of liver cancer prognosis. J Gastrointest Oncol 2024;15:2230-51. [Crossref] [PubMed]
3. Obeidat AE, Wong LL. Spontaneous Rupture of Hepatocellular Carcinoma: New Insights. J Clin Exp Hepatol 2022;12:483-91. [Crossref] [PubMed]
4. Zhu Q, Li J, Yan JJ, et al. Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol 2012;18:7302-7. [Crossref] [PubMed]
5. Xu Y, Zhu Z, Yu Z, et al. Relationship between spontaneous rupture of hepatocellular carcinoma (SRHCC) and long-term survival after anatomic liver resection. J Gastrointest Oncol 2025;16:2213-24. [Crossref] [PubMed]
6. Lee AJ, Wu AG, Yew KC, et al. Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis. World J Gastrointest Surg 2023;15:273-86.
7. Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191-8. [Crossref] [PubMed]
8. Sonoda T, Kanematsu T, Takenaka K, et al. Ruptured hepatocellular carcinoma evokes risk of implanted metastases. J Surg Oncol 1989;41:183-6. [Crossref] [PubMed]
9. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681-93. [Crossref] [PubMed]
10. Commin A, Metivier C, Allaire M, et al. Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma. Liver Int 2025;45:e70332. [Crossref] [PubMed]
11. Coccolini F, Sartelli M, Kluger Y, et al. The LIFE TRIAD of emergency general surgery. World J Emerg Surg 2022;17:41. [Crossref] [PubMed]
12. Cheo FY, Lim CHF, Chan KS, et al. The impact of waiting time and delayed treatment on the outcomes of patients with hepatocellular carcinoma: A systematic review and meta-analysis. Ann Hepatobiliary Pancreat Surg 2024;28:1-13. [Crossref] [PubMed]
13. Yap KY, Chi H, Ng S, et al. Effect of perioperative branched chain amino acids supplementation in liver cancer patients undergoing surgical intervention: A systematic review. World J Gastrointest Surg 2023;15:2596-618. [Crossref] [PubMed]
14. Hai HH, Aw P, Teng TZJ, et al. Perioperative steroid administration reduces overall complications in patients undergoing liver resection: A meta-analysis. World J Gastrointest Surg 2021;13:1079-94. [Crossref] [PubMed]
15. Chan KS, Shelat VG. The role of platelet-lymphocyte ratio in hepatocellular carcinoma: a valuable prognostic marker. Transl Cancer Res 2022;11:4231-4. [Crossref] [PubMed]